Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer...

Keywords

NivolumabMedicineInternal medicineRefractory (planetary science)PneumonitisClinical endpointLung cancerAdverse effectPembrolizumabResponse Evaluation Criteria in Solid TumorsCancerPhases of clinical researchSurrogate endpointProgressive diseaseClinical trialGastroenterologySurgeryOncologyImmunotherapyLungChemotherapy

Affiliated Institutions

Related Publications

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Martin Reck , Delvys Rodríguez‐Abreu , Andrew Robinson +15 more

In patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab was associated with significantly longer progression-free and overall survival...

2016 New England Journal of Medicine 9645 citations

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

Rita Nanda , Laura Q.M. Chow , Elizabeth Claire Dees +9 more

Purpose Immune checkpoint inhibition has been demonstrated to be an effective anticancer strategy. Several lines of evidence support the study of immunotherapy in triple-negativ...

2016 Journal of Clinical Oncology 1427 citations

Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non–Small-cell Lung Cancer

Charlotte Roach , Nancy Zhang , Ellie Corigliano +7 more

A companion diagnostic assay was codeveloped by Dako for pembrolizumab non–small-cell lung cancer clinical trials to detect PD-L1 expression by immunohistochemistry (IHC). This ...

2016 Applied immunohistochemistry & molecu... 346 citations

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

Luis Paz‐Ares , Alexander Luft , David Vicente +20 more

In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel resulted in si...

2018 New England Journal of Medicine 3472 citations

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

Julie R. Brahmer , Christina Lacchetti , Bryan J. Schneider +26 more

Purpose To increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events in patients treated with immune checkpoint i...

2018 Journal of Clinical Oncology 3484 citations

Publication Info

Year: 2015
Type: article
Volume: 16
Issue: 3
Pages: 257-265
Citations: 1406
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1406

OpenAlex

Cite This

APA Style

                            
                                
                                    Naiyer A. Rizvi, 
                                
                                    Julien Mazières, 
                                
                                    David Planchard
                                
                                et al.
                            
                            (2015). 
                            Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. 
                            The Lancet Oncology
                            , 16
                            (3)
                            , 257-265.
                            https://doi.org/10.1016/s1470-2045(15)70054-9
                        

Identifiers

DOI: 10.1016/s1470-2045(15)70054-9